Studies presented at Obesity Week 2025 validate the test’s ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients.
I met a mix of biotech and healthtech companies at HLTH affecting everything from drug development, drug efficacy to controlling specialty care costs and managing chronic diseases.
Launching at HLTH 2024, the groundbreaking partnership offers payers, health systems, employers, and life science organizations access to personalized obesity care and treatment planning based on a patient’s DNA.
Respondents ages 18 to 65 highlight urgency for medical recognition, scientifically proven interventions, and genetic testing for personalized obesity treatment.
In this episode of Causes or Cures, Dr. Eeks chats with Dr. Andres Acosta MD PHD about the identification of 4 phenotypes for obesity and how they can revolutionize the future of obesity treatment.
For many patients, GLP-1 drugs like Ozempic and Wegovy lead to substantial weight loss. But some see much less benefit, and researchers are trying to figure out why.
A new set of objective and simple phenotyping tests that categorize patients by four distinct subtypes of obesity is set to disrupt obesity care, by enabling the tailoring of therapy to a patient's syndrome to create care that is more successful and cost-effective.
Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.
